Effects of aclidinium on determinants of COPD severity: Symptoms and quality of life

Marco Contoli, Paolo Solidoro, Fabiano Di Marco, Nicola Scichilone, Angelo Corsico, Fulvio Braido, Pierachille Santus

Research output: Contribution to journalReview article

Abstract

The pathophysiology of chronic obstructive pulmonary disease (COPD) includes persistent airflow limitation, altered gas exchange, and enhanced chronic inflammatory response. According to disease severity in individual patients, exacerbations and comorbidities frequently occur. The overall nocturnal and daily symptoms have a strong impact on patient quality of life and clinical outcomes. Bronchodilators, by targeting two important aspects of COPD pathophysiology, ie, bronchoconstriction and lung hyperinflation, are the mainstay of therapy for COPD. Aclidinium bromide in particular is an anticholinergic molecule, approved for maintenance bronchodilator treatment of stable COPD, that combines high antimuscarinic activity with strong kinetic selectivity for the M3 receptor subtype. Moreover, the elevated plasma clearance of aclidinium has been related to low systemic bioavailability and low incidence of anticholinergic adverse events, whereas the reduced residence time at M2 receptors provides good cardiovascular safety. Altogether, these characteristics result in a high safety and tolerability profile. This review aims to reappraise the contribution of symptoms and of the level of quality of life determinants on COPD severity and to evaluate how therapeutic strategies with aclidinium may positively impact on these specific determinants of disease severity.

Original languageEnglish (US)
Pages (from-to)3043-3050
Number of pages8
JournalInternational Journal of COPD
Volume11
Issue number1
DOIs
StatePublished - Dec 5 2016
Externally publishedYes

Fingerprint

Chronic Obstructive Pulmonary Disease
Quality of Life
Bronchodilator Agents
Cholinergic Antagonists
Safety
Muscarinic Antagonists
Bronchoconstriction
Biological Availability
Comorbidity
Therapeutics
Gases
Maintenance
Lung
Incidence

Keywords

  • Aclidinium
  • COPD
  • Daily symptoms
  • LAMA
  • Quality of life

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Contoli, M., Solidoro, P., Di Marco, F., Scichilone, N., Corsico, A., Braido, F., & Santus, P. (2016). Effects of aclidinium on determinants of COPD severity: Symptoms and quality of life. International Journal of COPD, 11(1), 3043-3050. https://doi.org/10.2147/COPD.S122433

Effects of aclidinium on determinants of COPD severity : Symptoms and quality of life. / Contoli, Marco; Solidoro, Paolo; Di Marco, Fabiano; Scichilone, Nicola; Corsico, Angelo; Braido, Fulvio; Santus, Pierachille.

In: International Journal of COPD, Vol. 11, No. 1, 05.12.2016, p. 3043-3050.

Research output: Contribution to journalReview article

Contoli, M, Solidoro, P, Di Marco, F, Scichilone, N, Corsico, A, Braido, F & Santus, P 2016, 'Effects of aclidinium on determinants of COPD severity: Symptoms and quality of life', International Journal of COPD, vol. 11, no. 1, pp. 3043-3050. https://doi.org/10.2147/COPD.S122433
Contoli M, Solidoro P, Di Marco F, Scichilone N, Corsico A, Braido F et al. Effects of aclidinium on determinants of COPD severity: Symptoms and quality of life. International Journal of COPD. 2016 Dec 5;11(1):3043-3050. https://doi.org/10.2147/COPD.S122433
Contoli, Marco ; Solidoro, Paolo ; Di Marco, Fabiano ; Scichilone, Nicola ; Corsico, Angelo ; Braido, Fulvio ; Santus, Pierachille. / Effects of aclidinium on determinants of COPD severity : Symptoms and quality of life. In: International Journal of COPD. 2016 ; Vol. 11, No. 1. pp. 3043-3050.
@article{9821ed9f0f48470ea1269a48dbf3b0bf,
title = "Effects of aclidinium on determinants of COPD severity: Symptoms and quality of life",
abstract = "The pathophysiology of chronic obstructive pulmonary disease (COPD) includes persistent airflow limitation, altered gas exchange, and enhanced chronic inflammatory response. According to disease severity in individual patients, exacerbations and comorbidities frequently occur. The overall nocturnal and daily symptoms have a strong impact on patient quality of life and clinical outcomes. Bronchodilators, by targeting two important aspects of COPD pathophysiology, ie, bronchoconstriction and lung hyperinflation, are the mainstay of therapy for COPD. Aclidinium bromide in particular is an anticholinergic molecule, approved for maintenance bronchodilator treatment of stable COPD, that combines high antimuscarinic activity with strong kinetic selectivity for the M3 receptor subtype. Moreover, the elevated plasma clearance of aclidinium has been related to low systemic bioavailability and low incidence of anticholinergic adverse events, whereas the reduced residence time at M2 receptors provides good cardiovascular safety. Altogether, these characteristics result in a high safety and tolerability profile. This review aims to reappraise the contribution of symptoms and of the level of quality of life determinants on COPD severity and to evaluate how therapeutic strategies with aclidinium may positively impact on these specific determinants of disease severity.",
keywords = "Aclidinium, COPD, Daily symptoms, LAMA, Quality of life",
author = "Marco Contoli and Paolo Solidoro and {Di Marco}, Fabiano and Nicola Scichilone and Angelo Corsico and Fulvio Braido and Pierachille Santus",
year = "2016",
month = "12",
day = "5",
doi = "10.2147/COPD.S122433",
language = "English (US)",
volume = "11",
pages = "3043--3050",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Effects of aclidinium on determinants of COPD severity

T2 - Symptoms and quality of life

AU - Contoli, Marco

AU - Solidoro, Paolo

AU - Di Marco, Fabiano

AU - Scichilone, Nicola

AU - Corsico, Angelo

AU - Braido, Fulvio

AU - Santus, Pierachille

PY - 2016/12/5

Y1 - 2016/12/5

N2 - The pathophysiology of chronic obstructive pulmonary disease (COPD) includes persistent airflow limitation, altered gas exchange, and enhanced chronic inflammatory response. According to disease severity in individual patients, exacerbations and comorbidities frequently occur. The overall nocturnal and daily symptoms have a strong impact on patient quality of life and clinical outcomes. Bronchodilators, by targeting two important aspects of COPD pathophysiology, ie, bronchoconstriction and lung hyperinflation, are the mainstay of therapy for COPD. Aclidinium bromide in particular is an anticholinergic molecule, approved for maintenance bronchodilator treatment of stable COPD, that combines high antimuscarinic activity with strong kinetic selectivity for the M3 receptor subtype. Moreover, the elevated plasma clearance of aclidinium has been related to low systemic bioavailability and low incidence of anticholinergic adverse events, whereas the reduced residence time at M2 receptors provides good cardiovascular safety. Altogether, these characteristics result in a high safety and tolerability profile. This review aims to reappraise the contribution of symptoms and of the level of quality of life determinants on COPD severity and to evaluate how therapeutic strategies with aclidinium may positively impact on these specific determinants of disease severity.

AB - The pathophysiology of chronic obstructive pulmonary disease (COPD) includes persistent airflow limitation, altered gas exchange, and enhanced chronic inflammatory response. According to disease severity in individual patients, exacerbations and comorbidities frequently occur. The overall nocturnal and daily symptoms have a strong impact on patient quality of life and clinical outcomes. Bronchodilators, by targeting two important aspects of COPD pathophysiology, ie, bronchoconstriction and lung hyperinflation, are the mainstay of therapy for COPD. Aclidinium bromide in particular is an anticholinergic molecule, approved for maintenance bronchodilator treatment of stable COPD, that combines high antimuscarinic activity with strong kinetic selectivity for the M3 receptor subtype. Moreover, the elevated plasma clearance of aclidinium has been related to low systemic bioavailability and low incidence of anticholinergic adverse events, whereas the reduced residence time at M2 receptors provides good cardiovascular safety. Altogether, these characteristics result in a high safety and tolerability profile. This review aims to reappraise the contribution of symptoms and of the level of quality of life determinants on COPD severity and to evaluate how therapeutic strategies with aclidinium may positively impact on these specific determinants of disease severity.

KW - Aclidinium

KW - COPD

KW - Daily symptoms

KW - LAMA

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=85007486303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007486303&partnerID=8YFLogxK

U2 - 10.2147/COPD.S122433

DO - 10.2147/COPD.S122433

M3 - Review article

C2 - 27980401

AN - SCOPUS:85007486303

VL - 11

SP - 3043

EP - 3050

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

IS - 1

ER -